Key result
Empagliflozin therapy in a 78-year-old man with heart failure and preserved ejection fraction improved symptoms from functional class III to II and decreased NT-proBNP levels from 662 to 517 ng/l over 3 months.
Why the study?
Does empagliflozin 10 mg daily improve symptoms and laboratory parameters in a patient with HFpEF?
Case Report (n=1)
Does empagliflozin 10 mg daily improve symptoms and laboratory parameters in a patient with HFpEF?
This case report demonstrates that empagliflozin 10 mg daily can rapidly improve symptoms, NT-proBNP, and renal function in a patient with HFpEF in routine clinical practice.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for empagliflozin in HFpEF; prospective trials needed before clinical adoption.
Sodiumglucose co-transporter 2 inhibitors - gliflozins - have a scientific evidence on efficacy in patients with heart failure regardless left ventricular ejection fraction. Gliflozins They reduced combined endpoint of cardiovascular mortality and heart failure hospitalization also in patients with heart failure and left ventricular ejection fraction above 40 %. We report a case study of a patient with new onset heart failure. Early initiation of therapy with empagliflozin was associated with an improvement of symptoms and laboratory parameters including NT-proBNP level.
No takes yet. Share an insight, caveat, or question.
Filip Málek (2023) conducted a case report in Heart failure with preserved ejection fraction (n=1). Empagliflozin was evaluated on Symptomatology and laboratory parameters (including NT-proBNP). Empagliflozin therapy in a 78-year-old man with heart failure and preserved ejection fraction improved symptoms from functional class III to II and decreased NT-proBNP levels from 662 to 517 ng/l over 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: